Company to Host Surgical Innovation Lab With Key European and U.S. Thought Leaders for the DenerveX(TM) System Technology in Further Preparation for Future EU Launch
ATLANTA, GA--(Marketwired - Sep 10, 2015) - Medovex Corp. (
As part of the Company's pre-launch strategy, Medovex will host a Surgical Innovation Lab with leading European and U.S. spine surgeons at the NASS meeting. Dr. Scott Haufe M.D. and members of the Company's Executive team, will be demonstrating the Company's DenerveX System technology, as well as hosting a private business suite to meet with key opinion leaders from Europe and the U.S.
The Company's patented DenerveX System, currently in development and not yet commercially available, is designed to provide relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.
The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.
Mr. Patrick Kullmann, Medovex President and COO, stated, "We are excited to be participating in NASS 2015, as well as hosting a Surgical Innovation Lab with Dr. Haufe for these leading spine surgeons. The purpose of the Surgical Innovation Lab is to provide a training experience as part of our pre-European market launch activities by inviting members of our clinical advisory board and some of the leading European and U.S. based key opinion leaders.
Kullmann continued, "It's a single location to meet with others from around the globe to collaborate, hear differing perspectives, develop relationships and interact with practitioners from other specialties, something we view as very important as we continue to proceed in the later stages of the development of our DenerveX technology and begin the pre-launch process. This lab, along with the identification of distribution partners, will prepare us well for our future launch outside the U.S."
Dr. Scott Haufe is co-founder of Medovex, a member of the Board of Directors and the Medical Director of the Company. Dr. Haufe is a board certified physician in the fields of Anesthesiology, Pain Medicine and Hospice / Palliative Medicine. He began his career in the field of Anesthesiology where he served as Chief of Anesthesiology and Pain Management with St. Lucie Anesthesia Associates while continuing his passion for research.
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
About NASS 2015
A one-of-a-kind meeting, where spine care professionals from around the globe will share the latest information, innovative techniques and procedures, best practices, and new technologies. The Annual Meeting provides a unique opportunity for you to learn and gain skills through dynamic and challenging educational programs, the ability to network and build relationships with your colleagues and leading experts in spine care.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.